ArticleCureus2025
Investigating the Pathological Relevance of N-acylsphingosine Amidohydrolase 2 (ASAH2) and Related Proteins in Alzheimer's Disease.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Background Alzheimer's disease (AD) is a progressive neurodegenerative disorder mainly characterized by progressive cognitive decline and memory loss. Identifying candidate biomarkers before the clinical onset of AD is crucial for enabling earlier diagnosis and timely therapeutic intervention. Among different molecular targets, N-acylsphingosine amidohydrolase 2 (ASAH2), a key enzyme in ceramide metabolism, has been linked to many neurodegenerative diseases, including AD. This study investigates ASAH2 expression in human serum and AD mouse models to explore its potential as an early biomarker and to understand its involvement in AD progression. Methods The protein levels in the serum of pre-AD, mild cognitive impairment, and control patients were measured using the SOMAscan assay platform (SomaLogic Inc., CO, USA) to identify potential candidate biomarkers for preclinical AD. ASAH2 expression at different Alzheimer's stages of triple transgenic (3x-TG) Alzheimer's mice organs and tissues was analyzed. Human serums and hepatoblastoma cells (also referred to as HepG2 cells) were stained and quantified with ASAH2, membrane, and vesicle trafficking proteins. Results We found that neutral ceramidase (ASAH2/ASAH2B) and sortilin-related VPS10 domain-containing receptor 2 (SORCS2) were significantly elevated in the serum of individuals who later developed Alzheimer's dementia. Similarly, 3x-TG AD mice showed an increased ASAH2 expression at three months, followed by a marked decline at 14 months compared to age-matched non-3x-TG controls. In non-3x-TG mice, ASAH2 was highly expressed in visceral organs such as the heart, liver, kidneys, lungs, and stomach, but was nearly absent in the brain. Ingenuity pathway analysis revealed dysregulation in lipid trafficking and inflammatory pathways. Additionally, we observed elevated lysosomal-associated membrane protein 1 (LAMP1) and reduced levels of filamin A and RAB7 (a member of the RAS oncogene family) in the pre-AD mild cognitive impairment group. Conclusion Our findings suggest that ASAH2 may play a significant role in the pathogenesis of AD, potentially contributing to early molecular changes that precede clinical symptoms. In addition, the identification of a subgroup of lipid- and membrane-associated proteins provides promising candidates for predictive biomarkers that could facilitate earlier diagnosis and offer new insights into the mechanisms underlying disease progression and possible therapeutic targets for AD prevention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.